791 related articles for article (PubMed ID: 28526063)
1. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
2. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
[TBL] [Abstract][Full Text] [Related]
3. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
[TBL] [Abstract][Full Text] [Related]
4. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1).
Möhle R; Failenschmid C; Bautz F; Kanz L
Leukemia; 1999 Dec; 13(12):1954-9. PubMed ID: 10602415
[TBL] [Abstract][Full Text] [Related]
6. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.
Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G
HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875
[TBL] [Abstract][Full Text] [Related]
7. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
Qi J; Chen SS; Chiorazzi N; Rader C
Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
[TBL] [Abstract][Full Text] [Related]
8. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
Zhang Y; Saavedra E; Tang R; Gu Y; Lappin P; Trajkovic D; Liu SH; Smeal T; Fantin V; De Botton S; Legrand O; Delhommeau F; Pernasetti F; Louache F
Sci Rep; 2017 Aug; 7(1):7305. PubMed ID: 28779088
[TBL] [Abstract][Full Text] [Related]
9. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Niedermeier M; Hennessy BT; Knight ZA; Henneberg M; Hu J; Kurtova AV; Wierda WG; Keating MJ; Shokat KM; Burger JA
Blood; 2009 May; 113(22):5549-57. PubMed ID: 19318683
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
11. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
12. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Pavlasova G; Borsky M; Seda V; Cerna K; Osickova J; Doubek M; Mayer J; Calogero R; Trbusek M; Pospisilova S; Davids MS; Kipps TJ; Brown JR; Mraz M
Blood; 2016 Sep; 128(12):1609-13. PubMed ID: 27480113
[TBL] [Abstract][Full Text] [Related]
14. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
15. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
[TBL] [Abstract][Full Text] [Related]
16. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
Burger JA; Tsukada N; Burger M; Zvaifler NJ; Dell'Aquila M; Kipps TJ
Blood; 2000 Oct; 96(8):2655-63. PubMed ID: 11023495
[TBL] [Abstract][Full Text] [Related]
17. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
18. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
Matas-Céspedes A; Vidal-Crespo A; Rodriguez V; Villamor N; Delgado J; Giné E; Roca-Ho H; Menéndez P; Campo E; López-Guillermo A; Colomer D; Roué G; Wiestner A; Parren PW; Doshi P; van Bueren JL; Pérez-Galán P
Clin Cancer Res; 2017 Mar; 23(6):1493-1505. PubMed ID: 27637890
[No Abstract] [Full Text] [Related]
19. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.
Burger JA; Burger M; Kipps TJ
Blood; 1999 Dec; 94(11):3658-67. PubMed ID: 10572077
[TBL] [Abstract][Full Text] [Related]
20. CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer S; Hutterer E; Hinterseer E; Brachtl G; Asslaber D; Krenn PW; Girbl T; Berghammer P; Geisberger R; Egle A; Zucchetto A; Kruschinski A; Gattei V; Chigaev A; Greil R; Hartmann TN
Oncotarget; 2015 May; 6(14):12048-60. PubMed ID: 25895128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
